MENLO PARK, Calif.--(BUSINESS WIRE)--Ceterix® Orthopaedics, Inc., a developer of novel surgical tools for minimally invasive soft tissue procedures, announced today it received a Silver award at the 2015 Edison Awards in the surgical tools category (Science/Medical/Dental). This prestigious award, named after Thomas Alva Edison, recognizes the best and brightest in innovation, creativity, and ingenuity in the global economy.
The NovoStitch® suture passer allows orthopaedic surgeons to more easily address complex knee injuries that have been traditionally difficult to repair, enabling the placement of a circumferential compression stitch in the knee meniscus, which is tightly surrounded by critical structures such as nerves, arteries and cartilage. This enables orthopaedic surgeons to treat complex injuries that have not been amenable to repair in the past. NovoStitch technology can also be utilized in minimally invasive hip and shoulder procedures.
Meniscus surgery is the single most common arthroscopic procedure in the United States, with roughly one million performed annually. Ceterix’s technology is currently in use by more than 300 U.S. physicians.
“This is a great honor for our founder, Dr. Justin Saliman, and our R&D team,” said John McCutcheon, president and CEO. “We are pleased to be included with the great innovators recognized by the Edison Awards.”
Winners of The Edison Award are ranked highest among their peers in concept, value, delivery and impact. The members of the Edison Awards Steering Committee are senior executives with diverse marketing, scientific, and business backgrounds who monitor the development and successful launch of innovative products each year.
For more information on the Edison Awards and a list of past winners please visit www.edisonawards.com.
About Ceterix Orthopaedics
Ceterix® Orthopaedics develops surgical tools that expand and improve what is possible for physicians who treat soft tissue injuries such as meniscus tears, hip and shoulder labrum tears, and rotator cuff tears. Founded in 2010 with the vision of improving outcomes of arthroscopic procedures, Ceterix’s novel suture passing device enables surgeons to place suture patterns that were previously only possible in open procedures, or not at all. The NovoStitch suture passer is indicated for passing suture through soft tissue in orthopaedic surgery (the specific indication of meniscal tears repair has not been cleared by the FDA). The company is based in Menlo Park, Calif. and is backed by investors Novo Ventures, Versant Ventures and 5AM Ventures. For more information, please visit http://www.ceterix.com/.